{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:27:05Z","timestamp":1760909225126,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","award":["No number"],"award-info":[{"award-number":["No number"]}],"id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To assess the efficacy of radioimmunotherapy (RIT) with <jats:sup>90<\/jats:sup>yttrium-ibrutinib-tiuxetan (90Y-IT) in mantle cell lymphoma, data from 90 patients registered in the RIT Network with a median follow-up (FU) of 5.5\u00a0years after RIT were evaluated. 90Y-IT was given as first-line therapy in 45 (50%) and for relapse in 45 (50%) patients. Most patients received 90Y-IT as consolidation after chemoimmunotherapy in first line (98%) and in relapse (53%). As a first-line treatment, 30 patients (pts.) (67%) achieved CR, 10 pts. (22%) PR%. and 1\u00a0pt. (2%) PD, and for 4 pts. (9%), no response data was available. At relapse, CR was achieved in 17 pts. (38%), PR in 6 pts. (13%), SD in 2 pts. (4%), and 6 pts. (13%) had PD, while the response was not documented for 14 pts. (31%). After a median FU of 5.5\u00a0years, median PFS for all patients was 2.11 (95% CI, 1.03\u20132.32) years, and median OS was 4.05 (95% CI, 2.79\u20137.21) years. Eleven pts. (12.2%) developed second malignancy. In conclusion, this is the largest report of MCL pts. treated with 90Y-IT to date. 90Y-IT was most often used as consolidation after first- and second-line chemotherapy and may improve the results achieved using chemoimmunotherapy alone. However, the results are less encouraging compared to treatment with small molecules such as ibrutinib.<\/jats:p>","DOI":"10.1007\/s00277-020-03956-0","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T06:02:51Z","timestamp":1583215371000},"page":"1073-1079","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-3274","authenticated-orcid":false,"given":"Karin","family":"Hohloch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Windemuth-Kieselbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Cacchione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian W.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"issue":"suppl_4","key":"3956_CR1","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M, Committee EG (2017) Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv62\u2013iv71. https:\/\/doi.org\/10.1093\/annonc\/mdx223","journal-title":"Ann Oncol"},{"issue":"6","key":"3956_CR2","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Prochazka V, Di Raimondo F, Ribrag V, Uppenkamp M, Andre M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH (2012) Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367(6):520\u2013531. https:\/\/doi.org\/10.1056\/NEJMoa1200920","journal-title":"N Engl J Med"},{"issue":"13","key":"3956_CR3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Du K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Bene MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O, Group L (2017) Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 377(13):1250\u20131260. https:\/\/doi.org\/10.1056\/NEJMoa1701769","journal-title":"N Engl J Med"},{"issue":"2","key":"3956_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/leu.2016.305","volume":"31","author":"MR Smith","year":"2017","unstructured":"Smith MR, Hong F, Li H, Gordon LI, Gascoyne RD, Paietta EM, Advani RH, Forero-Torres A, Horning SJ, Kahl BS (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31(2):517\u2013519. https:\/\/doi.org\/10.1038\/leu.2016.305","journal-title":"Leukemia"},{"key":"3956_CR5","doi-asserted-by":"publisher","unstructured":"Jurczak W, Gruszka AM, Sowa Staszczak A, Dlugosz-Danecka M, Szostek M, Zimowska-Curylo D, Giza A, Krawczyk K, Jakobczyk M, Hubalewska-Dydejczyk A, Szymczyk M, Wrobel T, Knopinska-Posluszny W, Kisiel E, Skotnicki A, Zinzani PL (2019) Consolidation with (90)Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre polish lymphoma research group trial, after 8-year long follow-up. Leuk Lymphoma:1\u20138. https:\/\/doi.org\/10.1080\/10428194.2019.1602261","DOI":"10.1080\/10428194.2019.1602261"},{"issue":"4","key":"3956_CR6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/leu.2015.215","volume":"30","author":"S Ferrero","year":"2016","unstructured":"Ferrero S, Pastore A, Scholz CW, Forstpointner R, Pezzutto A, Bergmann L, Trumper L, Finke J, Keller U, Ghione P, Passera R, Hiddemann W, Weigert O, Unterhalt M, Dreyling M (2016) Radioimmunotherapy in relapsed\/refractory mantle cell lymphoma patients: final results of a European MCL network phase II trial. Leukemia 30(4):984\u2013987. https:\/\/doi.org\/10.1038\/leu.2015.215","journal-title":"Leukemia"},{"issue":"6","key":"3956_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjh.15712","volume":"184","author":"K Hohloch","year":"2019","unstructured":"Hohloch K, Windemuth-Kieselbach C, Kolz J, Zinzani PL, Cacchione R, Jurczak W, Bischof Delaloye A, Trumper L, Scholz CW (2019) Radioimmunotherapy (RIT) for follicular lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry. Br J Haematol 184(6):949\u2013956. https:\/\/doi.org\/10.1111\/bjh.15712","journal-title":"Br J Haematol"},{"issue":"25","key":"3956_CR8","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","volume":"30","author":"MR Smith","year":"2012","unstructured":"Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, Kahl BS, Advani R, Hong F, Horning SJ (2012) Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: eastern cooperative oncology group study E1499. J Clin Oncol 30(25):3119\u20133126. https:\/\/doi.org\/10.1200\/JCO.2012.42.2444","journal-title":"J Clin Oncol"},{"issue":"9873","key":"3956_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von GU LC, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210. https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"issue":"10","key":"3956_CR10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F, Investigators LYM (2015) Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 372(10):944\u2013953. https:\/\/doi.org\/10.1056\/NEJMoa1412096","journal-title":"N Engl J Med"},{"issue":"19","key":"3956_CR11","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","volume":"123","author":"A Kolstad","year":"2014","unstructured":"Kolstad A, Laurell A, Jerkeman M, Gronbaek K, Elonen E, Raty R, Pedersen LB, Loft A, Bogsrud TV, Kimby E, Hansen PB, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Lehmann AK, Sundstrom C, Karjalainen-Lindsberg ML, Ralfkiaer E, Ehinger M, Delabie J, Bentzen H, Schildt J, Kostova-Aherdan K, Frederiksen H, Brown Pde N, Geisler CH, Nordic Lymphoma G (2014) Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma. Blood 123(19):2953\u20132959. https:\/\/doi.org\/10.1182\/blood-2013-12-541953","journal-title":"Blood"},{"issue":"31","key":"3956_CR12","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","volume":"27","author":"M Wang","year":"2009","unstructured":"Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A (2009) Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(31):5213\u20135218. https:\/\/doi.org\/10.1200\/JCO.2009.21.8545","journal-title":"J Clin Oncol"},{"issue":"6","key":"3956_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507\u2013516. https:\/\/doi.org\/10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"issue":"10020","key":"3956_CR14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S (2016) Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 387(10020):770\u2013778. https:\/\/doi.org\/10.1016\/S0140-6736(15)00667-4","journal-title":"Lancet"},{"issue":"8","key":"3956_CR15","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","volume":"32","author":"S Rule","year":"2018","unstructured":"Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M (2018) Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 32(8):1799\u20131803. https:\/\/doi.org\/10.1038\/s41375-018-0023-2","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-03956-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-020-03956-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-03956-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:29:56Z","timestamp":1614731396000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-020-03956-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["3956"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-03956-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"15 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}